连亏多年 国际医学拟定增10亿“补血”突围

Core Viewpoint - International Medicine (000516.SZ) plans to raise up to 1.008 billion yuan through a private placement, focusing on three main areas: smart healthcare projects, proton therapy center phase II, and working capital supplementation [2][4] Group 1: Fundraising and Investment Focus - The fundraising will allocate 638 million yuan to smart healthcare projects, nearly 100 million yuan to the proton therapy center phase II, and 270 million yuan for working capital [2] - The smart healthcare project aims to utilize idle assets to "activate stock assets," responding to both policy demands and the need for asset revitalization [2][5] - The company intends to use 270 million yuan from the fundraising to meet operational funding needs and optimize its capital structure [2][5] Group 2: Financial Challenges - As of September 30, 2025, the company's debt-to-asset ratio reached 68.80%, significantly higher than the industry average, with a sharp decline in cash reserves from 1.52 billion yuan at the end of 2021 to 331 million yuan [4][7] - The company has substantial short-term borrowings of 995 million yuan and non-current liabilities due within a year totaling 905 million yuan, leading to a total of nearly 1.9 billion yuan in rigid debt due within a year [4] - The company has faced significant losses over the past four years, with cumulative losses reaching 2.621 billion yuan [7] Group 3: Market Opportunities and Strategic Adjustments - The company views the fundraising as a strategic adjustment to address market changes, financial pressures, and idle assets [3] - The smart healthcare project and proton therapy center phase II are seen as key initiatives to capitalize on the "silver economy" and high-end medical development opportunities [4][6] - The proton therapy center phase II aims to fill a market gap in the northwest region, where no proton therapy centers are currently operational [6] Group 4: Operational Efficiency and Cost Management - The company is attempting to improve operational efficiency through clinical pathway management and cost structure optimization [8][9] - As of the third quarter of 2025, the company reported a management expense ratio of 10.99%, a decrease from previous periods, indicating initial success in cost control [8] - The company plans to continue enhancing service quality and patient experience while exploring various specialized medical fields to build competitive advantages [9]